Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma

Ilona Slusker Shternfeld, Jacques G.H. Lasudry, Richard J. Chappell, Soesiawati R. Darjatmoko, Daniel Albert

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.

Original languageEnglish (US)
Pages (from-to)1396-1401
Number of pages6
JournalArchives of ophthalmology
Volume114
Issue number11
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Retinoblastoma
Antineoplastic Agents
Transgenic Mice
Poisons
Mineral Oil
Neoplasms
Therapeutics
Luteinizing Hormone
Intraperitoneal Injections
Ro 23-7553
Control Groups
Injections
Wounds and Injuries

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. / Shternfeld, Ilona Slusker; Lasudry, Jacques G.H.; Chappell, Richard J.; Darjatmoko, Soesiawati R.; Albert, Daniel.

In: Archives of ophthalmology, Vol. 114, No. 11, 01.01.1996, p. 1396-1401.

Research output: Contribution to journalArticle

Shternfeld, Ilona Slusker ; Lasudry, Jacques G.H. ; Chappell, Richard J. ; Darjatmoko, Soesiawati R. ; Albert, Daniel. / Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. In: Archives of ophthalmology. 1996 ; Vol. 114, No. 11. pp. 1396-1401.
@article{8b97e2bf2dfd44b792580aa2c231a44f,
title = "Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma",
abstract = "Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21{\%} smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.",
author = "Shternfeld, {Ilona Slusker} and Lasudry, {Jacques G.H.} and Chappell, {Richard J.} and Darjatmoko, {Soesiawati R.} and Daniel Albert",
year = "1996",
month = "1",
day = "1",
doi = "10.1001/archopht.1996.01100140596012",
language = "English (US)",
volume = "114",
pages = "1396--1401",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma

AU - Shternfeld, Ilona Slusker

AU - Lasudry, Jacques G.H.

AU - Chappell, Richard J.

AU - Darjatmoko, Soesiawati R.

AU - Albert, Daniel

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.

AB - Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=0029966737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029966737&partnerID=8YFLogxK

U2 - 10.1001/archopht.1996.01100140596012

DO - 10.1001/archopht.1996.01100140596012

M3 - Article

VL - 114

SP - 1396

EP - 1401

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 11

ER -